Skip to content

Arecor

Sector:
Biotechnology
Invested in:
Calculus EIS, Calculus VCT

Arecor is a life sciences company focused on developing superior biopharmaceutical products via the application of its patented Arestat™ formulation technology platform.

The Arestat™ platform enables the development of superior biopharmaceutical products, primarily by enhancing their effectiveness and stability in liquid solutions. These include stable high concentration antibodies, reformulations of lyophilised (powder) products in to stable liquids, taking products out of the cold-chain (thermostability) as well as changing properties such as faster acting insulins. This technology is leveraged across two distinct business areas:

Proprietary Product Business

Using the Arestat™ platform, Arecor has developed its own portfolio of superior therapeutics, primarily focused on enabling improved treatments for diabetes via the innovative reformulation of already approved proteins and peptides. The Company’s lead products are Ultra-Rapid Acting Insulin, Stable Aqueous Glucagon and Ultra-Concentrated Rapid Acting Insulin, all of which are based on the reformulation of two previously approved peptides; insulin and glucagon. Both of these peptides are off-patent and are used within a variety of currently approved drugs and because insulin and glucagon’s safety and efficacy is already well known, Arecor will benefit from significant risk and cost being taken out of its drug development pathway.

Technology Partnering Business

Arecor partners worldwide with leading pharmaceutical and biotech companies, delivering to them superior reformulations of their proprietary products, which would otherwise not be possible using conventional formulation science. In so doing, such businesses are able to deliver improved products to patients as well as strengthen their patent protection and commercial market access in an increasingly competitive market.

Rationale

This investment will be used by Arecor to fund the development of the Company’s three lead proprietary diabetes products into Phase 1 clinical trials; to strengthen the management and sales team and to continue to drive growth in its technology partnering business.

Sarah Howell, Arecor CEO (pictured) says “We are delighted to have Calculus on board as an investor. Their investment will enable us to accelerate the delivery of significantly improved therapeutic treatments for people living with diabetes as well as to continue to develop and exploit our innovative formulation technology platform.  We are very much looking forward to working together more closely.”

Latest News

Arecor announces positive results from Phase 1 Trial of insulin product for diabetes patients

Arecor announces positive headline results from first phase 1 clinical trial of AT278 ultra-rapid acting insulin candidate for diabetes. AT278 delivers significantly accelerated PK/PD profile compared to Novorapid Potential to be first concentrated (500U/mL) ultra-rapid acting insulin product enabling miniaturisation of next generation insulin delivery devices. Potential to enable more effective disease management for insulin … Continued

Arecor Announce US Phase 1 Trial

Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today’s therapies to enable healthier lives, today announces U.S. Food and Drug Administration (FDA) clearance of the Group’s Investigational New Drug (IND) application for AT247, the Group’s proprietary wholly owned ultra-rapid insulin for the treatment of diabetes. The IND supports a Phase I clinical trial in … Continued

Calculus invests in Arecor following successful IPO

Arecor announced its admission to trading on AIM, a market operated by London Stock Exchange, on 3 June 2021. Admission follows a successful oversubscribed placing by Panmure Gordon, raising gross proceeds of £20 million at a price of 226 pence per share. On Admission the Company will have a market capitalisation of approximately £62.5 million. … Continued

Arecor granted key US patent

Cambridge, UK., 13 May 2021 – Arecor Limited (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces the grant by the United States Patent and Trademark Office of U.S. Utility Patent No. 10,925,965 B2, a patent that contributes to the Company’s global patent portfolio underpinning its ArestatTM technology … Continued